Small-cell carcinoma

Last updated
Small-cell carcinoma
Other namesSmall-cell lung cancer,
oat-cell carcinoma
Small cell lung cancer - cytology.jpg
Micrograph of a small-cell carcinoma of the lung showing cells with nuclear moulding, minimal amount of cytoplasm and stippled chromatin. FNA specimen. Field stain.
Specialty Oncology   OOjs UI icon edit-ltr-progressive.svg

Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung, [1] although it can occasionally arise in other body sites, such as the cervix, [2] prostate, [3] and gastrointestinal tract. Compared to non-small cell carcinoma, small cell carcinoma is more aggressive, with a shorter doubling time, higher growth fraction, and earlier development of metastases. [4]

Contents

Extensive stage small cell lung cancer (SCLC) is classified as a rare disorder. [5] Ten-year relative survival rate (combined limited and extensive SCLC) is 3.5% (4.3% for women, 2.8% for men). [6] Survival can be higher or lower based on a combination of factors including stage, age, sex and race. [7] While all lung cancers are associated with tobacco smoking, SCLC is very strongly associated with tobacco smoking. [4]

Types of small-cell carcinomas

Small-cell lung cancer

Small-cell lung carcinoma (SCLC) has long been divided into two clinicopathological stages, termed limited stage (LS) and extensive stage (ES). [8] The stage is generally determined by the presence or absence of metastases, whether or not the tumor appears limited to the thorax, and whether or not the entire tumor burden within the chest can feasibly be encompassed within a single radiotherapy portal. [9] In general, if the tumor is confined to one lung and the lymph nodes close to that lung, the cancer is said to be LS. If cancer has spread beyond that, it is said to be ES.

Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women. When associated with the lung, SCLC is sometimes called "oat cell carcinoma" due to the flat cell shape and scanty cytoplasm. Small cell mesothelioma – an extremely rare subtype of lung cancer – can be mistaken for small cell lung cancer. [10]

Small-cell carcinoma is most often more rapidly and widely metastatic than non-small-cell lung carcinoma [11] (and hence staged differently). There is usually early involvement of the hilar and mediastinal lymph nodes. [12] The mechanisms of its metastatic progression are not well understood. [13]

Combined small-cell lung carcinoma

When SCLC is found with one or more differentiated forms of lung cancer, such as squamous cell carcinoma or adenocarcinoma, the malignant tumor is then diagnosed and classified as a combined small cell lung carcinoma (c-SCLC). [14] Small-cell lung carcinoma can occur in combination with a wide variety of other histological variants of lung cancer, [14] including extremely complex malignant tissue admixtures. [15] [16] C-SCLC is the only currently recognized subtype of SCLC. [14]

Extrapulmonary small-cell carcinoma

Very rarely, the primary site for small-cell carcinoma is outside of the lungs and pleural space; in these cases, it is referred to as extrapulmonary small-cell carcinoma (EPSCC). Outside of the respiratory tract, small-cell carcinoma can appear in the cervix, prostate, liver, pancreas, gastrointestinal tract, or bladder. [17] It is estimated to account for 1,000 new cases a year in the U.S. Histologically similar to small-cell lung cancer, therapies for small-cell lung cancer are usually used to treat EPSCC. [18] First-line treatment is usually with cisplatin and etoposide. In Japan, first-line treatment is shifting to irinotecan and cisplatin. When the primary site is in the skin, it is referred to as a Merkel-cell carcinoma. [19]

Extrapulmonary small-cell carcinoma localized in the lymph nodes

This is an extremely rare type of small cell, and there has been little information in the scientific community. It appears to occur in only one or more lymph nodes, and nowhere else in the body. Treatment is similar to small cell lung cancer, but survival rates are much higher than other small-cell carcinomas. [20]

Small-cell carcinoma of the prostate

Small-cell carcinoma of the prostate (SCCP) is a rare form of prostate cancer (approximately 1% of prostate cancers). [21] Symptomatic metastasis of SCCP to the brain is rare, and carries a poor prognosis. [22]

Signs and symptoms

Frontal chest X-ray showing a probable S2-S3 small cell carcinoma in the right side lung. LK-small cell3683.jpg
Frontal chest X-ray showing a probable S2–S3 small cell carcinoma in the right side lung.

Small-cell carcinoma of the lung usually presents in the central airways and infiltrates the submucosa leading to narrowing of bronchial airways. Common symptoms include cough, dyspnea, weight loss, and debility. Over 70% of patients with small-cell carcinoma present with metastatic disease; common sites include liver, adrenals, bone, and brain. [23] [24]

Due to its high grade neuroendocrine nature, small-cell carcinomas can produce ectopic hormones, including adrenocorticotropic hormone (ACTH) and anti-diuretic hormone (ADH). Ectopic production of large amounts of ADH leads to syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH). [25] [12] Lambert–Eaton myasthenic syndrome is a well-known paraneoplastic condition linked to small-cell carcinoma. [26] Approximately half of all individuals diagnosed with Lambert–Eaton myasthenic syndrome will eventually be found to have a small-cell carcinoma of the lung. [26]

Genetics

TP53 is mutated in 70 to 90% of SCLCs. RB1 and the retinoblastoma pathway are inactivated in most SCLCs. PTEN is mutated in 2 to 10%. MYC amplifications and amplification of MYC family members are found in 30% of SCLCs. Loss of heterozygocity on chromosome arm 3p is found in more than 80% of SCLCs, including the loss of FHIT. [27] One hundred translocations have been reported in SCLCs. [28] [29]

Diagnosis

Histopathology of small-cell carcinoma, with typical findings. Histopathology of small cell carcinoma, annotated.png
Histopathology of small-cell carcinoma, with typical findings.
Histopathologic image of small-cell carcinoma of the lung. CT-guided core needle biopsy. H&E stain. Lung small cell carcinoma (1) by core needle biopsy.jpg
Histopathologic image of small-cell carcinoma of the lung. CT-guided core needle biopsy. H&E stain.

Small-cell carcinoma is an undifferentiated neoplasm composed of primitive-appearing cells. As the name implies, the cells in small-cell carcinomas are smaller than normal cells, and barely have room for any cytoplasm. Some researchers identify this as a failure in the mechanism that controls the size of the cells. [31]

At the time of diagnosis, 60–70% of people already have metastases. [13]

Treatment

LS-SCLC

In cases of LS-SCLC, combination chemotherapy is administered together with concurrent chest radiotherapy. [32] [33] [34] Chest radiotherapy has been shown to improve survival in LS-SCLC. [35] Because SCLC usually metastasizes widely very early on in the natural history of the tumor, and because nearly all cases respond dramatically to chemotherapy and/or radiotherapy, there has been little role for surgery in this disease since the 1970s. [36] However, in cases of small, asymptomatic, node-negative SCLC's ("very limited stage"), surgical excision may improve survival when used prior to chemotherapy. [37]

ES-SCLC

In ES-SCLC, platinum-based combination chemotherapy is the standard of care. [38]

Combination chemotherapy consists of a wide variety of agents, including cisplatin, cyclophosphamide, vincristine and carboplatin. Response rates are high even in extensive disease, with between 15% and 30% of subjects having a complete response to combination chemotherapy, and the vast majority having at least some objective response. Responses in ES-SCLC are often of short duration, and the evidence surrounding the risk of treatment compared to the potential benefit of chemotherapy for people who have extensive SCLC is not clear. [38]

Chemotherapy

Small-cell lung cancer is most commonly treated with chemotherapy in a combination of two drugs, which is more effective than one drug alone.

  1. Cisplatin and etoposide,
  2. Carboplatin and etoposide.

Cisplatin-resistance

The drug paclitaxel may be useful in the treatment of cisplatin-resistant cancer. About 68.1% of cisplatin-resistant cells appear to be sensitive to paclitaxel and 66.7% of paclitaxel-resistant cells to cisplatin. The mechanism for this activity is unknown. [39] Paclitaxel-based chemotherapy showed modest activity in SCLC patients refractory to both etoposide- and camptothecin-based chemotherapy. [40] The newer agent lurbinectedin is active in relapsed SCLC and was approved for medical use in the United States in June 2020. [41] [42] [43] [44] [45]

Immunotherapy

The FDA has approved three immunotherapies for small cell lung cancer:

Canadian regulator rejected funding Tecentriq (Atezolizumab) for extensive stage small-cell lung cancer in 2020 "as too costly" followed by United Kingdom also citing "drug’s cost-effectiveness." [52] [53]

Radiation therapy

Chest radiation helps SCLC patients live longer by killing cancer cells and helping prevention of cancer recurrence. [54] Another type of radiation, prophylactic cranial radiation, prevents central nervous system recurrence and can improve survival in patients with good performance status who have had a complete response or a very good partial response to chemoradiation in LD or chemotherapy in ED. [33]

In case of relapse

If small cell lung cancer comes back after treatment, the following combination of drugs may be used as a salvage therapy: [55]

  1. Cyclophosphamide (Cytoxan, Procytox),
  2. Doxorubicin (Adriamycin) and
  3. Vincristine (Oncovin)
  4. Paclitaxel (Taxol)
  5. Irinotecan (Camptosar) [56]

Guidelines recommended as of 2018 that patients who relapse > 6 months from initial therapy should be retreated with the original chemotherapy regimen. For patients who relapse in < 6 months, single-agent chemotherapy either topotecan second-line therapy, or paclitaxel can be used. [57]

Novel agents

Several newer agents, including temozolomide and bendamustine, have activity in relapsed SCLC. Of note, temozolomide yielded a response rate of 38% for brain metastases due to SCLC. [57]

In a clinical trial of 50 patients, combination of olaparib and temozolomide in relapsed small-cell lung cancer yielded an overall response rate of 41.7%, median progression-free survival 4.2 months, and overall survival was 8.5 months. [58]

Lurbinectedin showed increased overall survival rate in relapsed small cell lung cancer in a trial. [59] Lurbinectedin is As of 2019 available in the U.S. under an expanded access program (EAP). [60] [61] [62]

Trilaciclib, a CKD4/6 inhibitor, reduces chemotheraphy-induced toxicity in patients being treated for small-cell lung cancer. [63] [64] [65]

In 2021, the FDA approved trilaciclib (Cosela) as a treatment to reduce the frequency of chemotherapy-induced myelosuppression for patients receiving certain types of chemotherapy for extensive-stage small-cell lung cancer. [66]

Prognosis

As of 2015, 5-year survival rates for small cell lung cancer (extensive and limited) range between 3.6% and 32.2% for women, and between 2.2% and 24.5% for men. [67] Relative 5-year survival rate for both sexes has increased from 3.6% in 1975 to 6.7% in 2014. [67] In limited-stage disease, relative 5-year survival rate (both sexes, all races, all ages) is 21.3%; however, women have higher 5-year survival rates, 26.9%, and men have lower survival rates, 21.3%. [68] The prognosis is far grimmer in extensive-stage small-cell lung carcinoma where 5-year relative survival rate (both sexes, all races, all ages) is 2.8%; however, women have higher 5-year survival rates, 3.4%, and men have lower 5-year survival rates, 2.2%. [68]

Small-cell carcinoma is very responsive to chemotherapy and radiotherapy, and in particular, regimens based on platinum-containing agents. However, most people with the disease relapse and median survival remains low. The overall incidence and mortality rates of SCLC in the United States have decreased during the past few decades. [69]

Long-term survival of more than 5 years can be achieved with proper treatment. According to the 17th World Conference on Lung Cancer (WCLC), "patients who received chest radiation and prophylactic cranial irradiation along with a mean of five chemotherapy cycles could achieve a median survival of more than 5 years." [70] [67] In some cases, long-term survival of 10+ years is achieved with chemotherapy and radiation alone. [71] [72]

A 2023 article stated that the median overall survival is about 1 year, the worst of any lung cancer subtype. [73]

Epidemiology

Pie chart showing incidence of small-cell lung cancer (shown in red at right), as compared to other lung cancer types, with fractions of smokers versus non-smokers shown for each type. Pie chart of lung cancers.svg
Pie chart showing incidence of small-cell lung cancer (shown in red at right), as compared to other lung cancer types, with fractions of smokers versus non-smokers shown for each type.

Small cell lung carcinoma stand for 15% of lung cancers in the United States. [75] Small cell lung cancer occurs almost exclusively in smokers – most commonly in heavy smokers and rarely in non-smokers. [76] [77]

Society

In 2013, the US Congress passed the Recalcitrant Cancer Research Act, which mandated increased attention to certain recalcitrant cancers (cancers having a 5-year relative survival rate of less than 50%), including small cell lung cancer. That led to the National Cancer Institute supporting small cell–specific research. [78] [79]

Notable cases

Additional images

Related Research Articles

<span class="mw-page-title-main">Lung cancer</span> Malignant tumor characterized by uncontrolled cell growth in lung tissue

Lung cancer, also known as lung carcinoma, is a malignant tumor that begins in the lung. Lung cancer is caused by genetic damage to the DNA of cells in the airways, often caused by cigarette smoking or inhaling damaging chemicals. Damaged airway cells gain the ability to multiply unchecked, causing the growth of a tumor. Without treatment, tumors spread throughout the lung, damaging lung function. Eventually lung tumors metastasize, spreading to other parts of the body.

Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

<span class="mw-page-title-main">Non-small-cell lung cancer</span> Any type of epithelial lung cancer other than small-cell lung carcinoma

Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.

<span class="mw-page-title-main">Transitional cell carcinoma</span> Medical condition

Transitional cell carcinoma is a type of cancer that arises from the transitional epithelium, a tissue lining the inner surface of these hollow organs. It typically occurs in the urothelium of the urinary system; in that case, it is also called urothelial carcinoma. It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. Symptoms of urothelial carcinoma in the bladder include hematuria. Diagnosis includes urine analysis and imaging of the urinary tract (cystoscopy).

<span class="mw-page-title-main">Afatinib</span> Chemical compound

Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.

Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

<span class="mw-page-title-main">Combined small-cell lung carcinoma</span> Medical condition

Combined small cell lung carcinoma is a form of multiphasic lung cancer that is diagnosed by a pathologist when a malignant tumor, arising from transformed cells originating in lung tissue, contains a component of;small cell lung carcinoma (SCLC), admixed with one components of any histological variant of non-small cell lung carcinoma (NSCLC) in any relative proportion.

Treatment of lung cancer refers to the use of medical therapies, such as surgery, radiation, chemotherapy, immunotherapy, percutaneous ablation, and palliative care, alone or in combination, in an attempt to cure or lessen the adverse impact of malignant neoplasms originating in lung tissue.

Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.

<span class="mw-page-title-main">Crizotinib</span> ALK inhibitor for treatment of non-small-cell lung cancer

Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts as an ALK and ROS1 inhibitor.

<span class="mw-page-title-main">ALK positive lung cancer</span> Medical condition

ALK positive lung cancer is a primary malignant lung tumor whose cells contain a characteristic abnormal configuration of DNA wherein, most frequently, the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to the anaplastic lymphoma kinase (ALK) gene. Less frequently, there will be novel translocation partners for the ALK gene, in place of EML4. This abnormal gene fusion leads to the production of a protein that appears, in many cases, to promote and maintain the malignant behavior of the cancer cells.

<span class="mw-page-title-main">Nivolumab</span> Anticancer medication

Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction cancer. It is administered intravenously.

<span class="mw-page-title-main">Pembrolizumab</span> Pharmaceutical drug used in cancer treatment

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is administered by slow intravenous injection.

<span class="mw-page-title-main">PARAMOUNT trial</span> Clinical trial studying non-small-cell lung carcinoma

The PARAMOUNT trial is a clinical trial studying non-small-cell lung carcinoma (NSCLC). The trial was sponsored by Eli Lilly and Company and was conducted in several European countries and Canada. It was registered in November 2008 and was projected to end in September 2013.

<span class="mw-page-title-main">Sonidegib</span> Chemical compound

Sonidegib (INN), sold under the brand name Odomzo, is a medication used to treat cancer.

<span class="mw-page-title-main">Durvalumab</span> Pharmaceutical drug

Durvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

<span class="mw-page-title-main">Atezolizumab</span> Monoclonal anti-PD-L1 antibody

Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, but discontinued for use in triple-negative breast cancer (TNBC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).

<span class="mw-page-title-main">Limited-stage small cell lung carcinoma</span> Medical condition

Limited-stage small cell lung carcinoma (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which is small enough to be encompassed within a radiation portal. This generally includes cancer to one side of the lung and those might have reached the lymph nodes on the same side of the lung. 33% patients with small cell lung cancer are diagnosed with limited-stage small cell lung carcinoma when it is first found. Common symptoms include but are not limited to persistent cough, chest pain, rust-coloured sputum, shortness of breath, fatigue, weight loss, wheezing, hoarseness and recurrent respiratory tract infections such as pneumonia and bronchitis. Nervous system problems, Cushing syndrome and SIADH can also be associated with small cell lung cancer. Unlike extensive-stage small cell lung cancer, limited-stage small cell lung carcinoma is potentially curable. Standard treatments consist of surgery, platinum-based combination chemotherapy, thoracic irradiation, and prophylactic cranial irradiation. Patient five-year survival rate has significantly increased from 1% with surgery to 26% after the application of combination chemotherapy.

<span class="mw-page-title-main">Lurbinectedin</span> Chemical compound

Lurbinectedin, sold under the brand name Zepzelca, is a medication used for the treatment of small cell lung cancer.

References

  1. ↑ "small-cell carcinoma" at Dorland's Medical Dictionary
  2. ↑ Nasu K, Hirakawa T, Okamoto M, Nishida M, Kiyoshima C, Matsumoto H, et al. (March 2011). "Advanced small cell carcinoma of the uterine cervix treated by neoadjuvant chemotherapy with irinotecan and cisplatin followed by radical surgery". Rare Tumors. 3 (1): 18–20. doi:10.4081/rt.2011.e6. PMC   3070456 . PMID   21464879.
  3. ↑ Capizzello A, Peponi E, Simou N, Ntaskagiannis D, Tasiou I, Kamina S, Tsekeris P (February 2011). "Pure small cell carcinoma of the prostate: a case report and literature review". Case Reports in Oncology. 4 (1): 88–95. doi:10.1159/000324717. PMC   3072185 . PMID   21475596.
  4. 1 2 Basumallik, Neil; Agarwal, Manuj (2023), "Small Cell Lung Cancer", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   29494065 , retrieved 2023-10-02
  5. ↑ "Small Cell Lung Cancer". National Organization for Rare Disorders.
  6. ↑ "Small cell carcinoma of the Lung and Bronchus". Surveillance, Epidemiology, and End Results (SEER) Relative Survival Rates by Time Since Diagnosis. U.S. National Cancer Institute. 2016.
  7. ↑ "Small cell carcinoma of the Lung and Bronchus SEER 5-Year Relative Survival Rates, 2011-2017 By Sex and Race/Ethnicity, Ages 50-64, Distant". Surveillance, Epidemiology, and End Results (SEER) Relative Survival Rates by Time Since Diagnosis. U.S. National Cancer Institute. 2016.
  8. ↑ Chan BA, Coward JI (October 2013). "Chemotherapy advances in small-cell lung cancer". Journal of Thoracic Disease. 5 (Suppl 5): S565–S578. doi:10.3978/j.issn.2072-1439.2013.07.43. PMC   3804877 . PMID   24163749.
  9. ↑ Argiris A, Murren JR (2001). "Staging and clinical prognostic factors for small-cell lung cancer". Cancer Journal. 7 (5): 437–447. PMID   11693903.
  10. ↑ Selby K. "Small Cell Mesothelioma". The Mesothelioma Center.
  11. ↑ Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. p. 759. ISBN   978-0-7216-0187-8.
  12. 1 2 Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson (2007). "Ch. 13, box on morphology of small-cell lung carcinoma". Robbins Basic Pathology (8th ed.). Philadelphia: Saunders. ISBN   978-1-4160-2973-1.
  13. 1 2 Tammela T, Sage J (March 2020). "Investigating Tumor Heterogeneity in Mouse Models". Annual Review of Cancer Biology. 4 (1): 99–119. doi: 10.1146/annurev-cancerbio-030419-033413 . PMC   8218894 . PMID   34164589.
  14. 1 2 3 Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization Classification of Tumours. Lyon: IARC Press. ISBN   978-92-832-2418-1. Archived (PDF) from the original on 23 August 2009. Retrieved 27 March 2010.
  15. ↑ Pelosi G, Sonzogni A, Galetta D, Perrone F, Braidotti P, Manzotti M, et al. (April 2011). "Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type". Virchows Archiv. 458 (4): 497–503. doi:10.1007/s00428-010-1011-8. PMID   21210145. S2CID   19159554.
  16. ↑ Gotoh M, Yamamoto Y, Huang CL, Yokomise H (November 2004). "A combined small cell carcinoma of the lung containing three components: small cell, spindle cell and squamous cell carcinoma". European Journal of Cardio-Thoracic Surgery. 26 (5): 1047–1049. doi: 10.1016/j.ejcts.2004.08.002 . PMID   15519208.
  17. ↑ Ismaili N (November 2011). "A rare bladder cancer--small cell carcinoma: review and update". Orphanet Journal of Rare Diseases. 6 (75): 75. doi: 10.1186/1750-1172-6-75 . PMC   3253713 . PMID   22078012.
  18. ↑ Extrapulmonary Small Cell Carcinoma at eMedicine
  19. ↑ "Merkel-cell carcinima". Dynamed. Retrieved 2021-08-01.
  20. ↑ Cicin I, Usta U, Karagol H, Uzunoglu S, Kocak Z (2009). "Extrapulmonary small cell carcinoma localized in lymph nodes: is it a different clinical entity?". Acta Oncologica. 48 (3): 354–360. doi: 10.1080/02841860802495370 . PMID   18979286.
  21. ↑ Nutting C, Horwich A, Fisher C, Parsons C, Dearnaley DP (June 1997). "Small-cell carcinoma of the prostate". Journal of the Royal Society of Medicine. 90 (6): 340–341. doi:10.1177/014107689709000615. PMC   1296316 . PMID   9227387.
  22. ↑ Erasmus CE, Verhagen WI, Wauters CA, van Lindert EJ (November 2002). "Brain metastasis from prostate small cell carcinoma: not to be neglected". The Canadian Journal of Neurological Sciences. Le Journal Canadien des Sciences Neurologiques. 29 (4): 375–377. doi: 10.1017/S0317167100002250 . PMID   12463494.
  23. ↑ Nakazawa K, Kurishima K, Tamura T, Kagohashi K, Ishikawa H, Satoh H, Hizawa N (October 2012). "Specific organ metastases and survival in small cell lung cancer". Oncology Letters. 4 (4): 617–620. doi:10.3892/ol.2012.792. PMC   3506697 . PMID   23205072.
  24. ↑ Ko J, Winslow MM, Sage J (January 2021). "Mechanisms of small cell lung cancer metastasis". EMBO Molecular Medicine. 13 (1): e13122. doi:10.15252/emmm.202013122. PMC   7799359 . PMID   33296145.
  25. ↑ Babar SM (October 2013). "SIADH associated with ciprofloxacin". The Annals of Pharmacotherapy. 47 (10): 1359–1363. doi:10.1177/1060028013502457. PMID   24259701. S2CID   36759747.
  26. 1 2 Titulaer MJ, Verschuuren JJ (2008). "Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms". Annals of the New York Academy of Sciences. 1132 (1): 129–134. Bibcode:2008NYASA1132..129T. doi:10.1196/annals.1405.030. PMID   18567862. S2CID   22482871.
  27. ↑ "Lung: Translocations in Small Cell Carcinoma". atlasgeneticsoncology.org. Archived from the original on 30 January 2015. Retrieved 30 April 2018.
  28. ↑ "Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer". Archived from the original on 2016-05-29.
  29. ↑ "Atlas of Genetics and Cytogenetics in Oncology and Haematology". atlasgeneticsoncology.org. Archived from the original on 2011-02-23.
  30. ↑ Image by Mikael Häggström, MD. Source for findings: Caroline I.M. Underwood, M.D., Carolyn Glass, M.D., Ph.D. "Lung - Small cell carcinoma". Pathology Outlines.{{cite web}}: CS1 maint: multiple names: authors list (link) Last author update: 20 September 2022
  31. ↑ Leslie M (November 2011). "Mysteries of the cell. How does a cell know its size?". Science. 334 (6059): 1047–1048. doi:10.1126/science.334.6059.1047. PMID   22116854.
  32. ↑ "Limited-stage small cell lung cancer: Initial management". www.uptodate.com. UpToDate . Retrieved 2019-06-02.
  33. 1 2 "Small Cell Lung Cancer Treatment". National Cancer Institute. U.S.: National Cancer Institute, United States Department of Health and Human Services. 1980-01-01. Retrieved 2019-06-02.
  34. ↑ Sherman CA, Rocha Lima CM, Turrisi AT (October 2000). "Limited small-cell lung cancer: a potentially curable disease". Oncology. 14 (10): 1395–403, discussion 1403–4, 1409. PMID   11098505. Archived from the original on 2019-02-05. Retrieved 2021-08-01.
  35. ↑ Singer L, Yom SS (June 2015). "Consolidative radiation therapy for extensive-stage small cell lung cancer". Translational Lung Cancer Research. 4 (3): 211–214. doi:10.3978/j.issn.2218-6751.2015.04.02. PMC   4483471 . PMID   26207205.
  36. ↑ Mountain CF (September 1978). "Clinical biology of small cell carcinoma: relationship to surgical therapy". Seminars in Oncology. 5 (3): 272–279. PMID   211638.
  37. ↑ Shepherd FA (February 2010). "Surgery for limited stage small cell lung cancer: time to fish or cut bait". Journal of Thoracic Oncology. 5 (2): 147–149. doi: 10.1097/JTO.0b013e3181c8cbf5 . PMID   20101141.
  38. 1 2 Pelayo Alvarez M, Westeel V, Cortés-Jofré M, Bonfill Cosp X (November 2013). "Chemotherapy versus best supportive care for extensive small cell lung cancer". The Cochrane Database of Systematic Reviews (11): CD001990. doi:10.1002/14651858.CD001990.pub3. PMC   11364206 . PMID   24282143.
  39. ↑ Stordal B, Pavlakis N, Davey R (December 2007). "A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship" (PDF). Cancer Treatment Reviews. 33 (8): 688–703. doi:10.1016/j.ctrv.2007.07.013. hdl:2123/4068. PMID   17881133.
  40. ↑ Kim SH, Kim MJ, Kim YJ, Chang H, Kim JW, Lee JO, Lee KW, Kim JH, Bang SM, Lee JS (October 2017). "Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy". Medicine. 96 (42): e8176. doi:10.1097/MD.0000000000008176. PMC   5662365 . PMID   29049199.
  41. ↑ "Zepzelca: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 15 June 2020.
  42. ↑ "Zepzelca- lurbinectedin injection, powder, lyophilized, for solution". DailyMed. 15 June 2020. Retrieved 24 September 2020.
  43. ↑ "Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer" (Press release). Jazz Pharmaceuticals. 15 June 2020. Retrieved 15 June 2020– via PR Newswire.
  44. ↑ "FDA grants accelerated approval to lurbinectedin for metastatic small". U.S. Food and Drug Administration (FDA). 15 June 2020. Retrieved 16 June 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  45. ↑ "Drug Trials Snapshots: Zepzelca". U.S. Food and Drug Administration (FDA). 15 June 2020. Retrieved 28 June 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  46. ↑ "FDA Approves Opdivo for Small Cell Lung Cancer Treatment". Cure Today. 17 August 2018.
  47. ↑ "FDA Approves Opdivo (Nivolumab) for Small Cell Lung Cancer". cancer.org.
  48. ↑ "FDA approves atezolizumab for extensive-stage small cell lung cancer". U.S. Food and Drug Administration.
  49. ↑ "Concurrent Tecentriq Adds First Survival Benefit Seen in Small Cell Lung Cancer in 20 Years". curetoday.com. 25 September 2018.
  50. ↑ "FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer". U.S. Food and Drug Administration (FDA). 16 May 2024. Retrieved 17 May 2024.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  51. ↑ "FDA approves Imdelltra (tarlatamab-dlle), the first and only T-cell engager therapy for the treatment of extensive-stage small cell lung cancer" (Press release). Amgen. 16 May 2024. Retrieved 18 May 2024– via PR Newswire.
  52. ↑ "Canadian regulator considers changes to new drug pricing plan". Reuters. 20 February 2020. Archived from the original on February 22, 2020.
  53. ↑ "NICE Cites Cost in Deciding Against Atezolizumab for Frontline Advanced Small Cell Lung Cancer". Reuters. 6 January 2020.
  54. ↑ "Study: Chest Radiation Helps Small Cell Lung Cancer Patients Live Longer". cancer.org.
  55. ↑ "Treatment for Small Cell Lung Cancer". Canadian Cancer Society. May 2020.
  56. ↑ Mouri A, Yamaguchi O, Miyauchi S, Shiono A, Utsugi H, Nishihara F, et al. (January 2019). "Combination therapy with carboplatin and paclitaxel for small cell lung cancer". Respiratory Investigation. 57 (1): 34–39. doi:10.1016/j.resinv.2018.09.004. PMID   30528688. S2CID   54471245.
  57. 1 2 Qin A, Kalemkerian GP (June 2018). "Treatment Options for Relapsed Small-Cell Lung Cancer: What Progress Have We Made?". Journal of Oncology Practice. 14 (6): 369–370. doi: 10.1200/JOP.18.00278 . PMID   29894661.
  58. ↑ Farago AF, Yeap BY, Stanzione M, Hung YP, Heist RS, Marcoux JP, et al. (October 2019). "Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer". Cancer Discovery. 9 (10): 1372–1387. doi:10.1158/2159-8290.CD-19-0582. PMC   7319046 . PMID   31416802.
  59. ↑ Paz-Ares LG, Trigo Perez JM, Besse B, Moreno V, Lopez R, Sala MA, et al. (2019). "Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial". Journal of Clinical Oncology. 37 (supl, abstr 8506): 8506. doi:10.1200/JCO.2019.37.15_suppl.8506. S2CID   190884224.
  60. ↑ "PharmaMar and Bionical Emas Launch Expanded Access Program for Lurbinectedin in Relapsed Small Cell Lung Cancer in the U.S." Bionical Emas (Press release) – via www.prnewswire.com.
  61. ↑ Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Lopez Criado MP, et al. (October 2017). "Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study". Annals of Oncology. 28 (10): 2559–2566. doi: 10.1093/annonc/mdx357 . PMC   5834091 . PMID   28961837.
  62. ↑ Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Núñez R, Kahatt C, Paz-Ares L (January 2019). "ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line". Future Oncology. 15 (3): 231–239. doi:10.2217/fon-2018-0597. PMC   6331752 . PMID   30362375.
  63. ↑ Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, et al. (October 2019). "Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial". Annals of Oncology. 30 (10): 1613–1621. doi: 10.1093/annonc/mdz278 . PMC   6857609 . PMID   31504118.
  64. ↑ "FDA Grants Priority Review to Trilaciclib to Treat Patients with SCLC". Cancer Network. 17 August 2020. Retrieved 2020-12-04.
  65. ↑ "Trilaciclib | intravenous CDK4/6 inhibitor | G1 Therapeutics, Inc". www.g1therapeutics.com. Retrieved 2020-12-28.
  66. ↑ Office of the Commissioner (2021-02-12). "FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy". FDA. Retrieved 2021-02-16.
  67. 1 2 3 "Table 15.13: Small Cell Cancer of the Lung and Bronchus (Invasive), 5-Year Relative and Period Survival by Race, Sex, Diagnosis Year, Age and Stage at Diagnosis". The SEER Cancer Statistics Review 1975-2015. Surveillance, Epidemiology, and End Results (SEER), U.S. National Cancer Institute.
  68. 1 2 "Small cell carcinoma of the Lung and Bronchus SEER Relative Survival Rates by Time Since Diagnosis, 2004-2017 By Stage at Diagnosis, Male, All Races (includes Hispanic), All Ages". Surveillance, Epidemiology, and End Results (SEER) Relative Survival Rates by Time Since Diagnosis. U.S. National Cancer Institute. 2016.
  69. ↑ "Small Cell Lung Cancer Treatment". National Cancer Institute.
  70. ↑ Davenport L (20 December 2016). "Exceptional SCLC Survivors: 5-Year Median Survival". Medscape.
  71. ↑ Ketteler J (October 16, 2009). "Lung cancer report: "They said it was bronchitis"". Self.
  72. ↑ "Focus on immunotherapy and patient perspective highlight the IASLC 2019 Small Cell Lung Cancer Meeting". The International Association for the Study of Lung Cancer (IASLC). 2019.
  73. ↑ "SCLC Prognosis Remains 'Unsatisfactory' Despite Numerous Treatment Options". Cancer Network. 12 April 2023.
  74. ↑ Smokers defined as current or former smoker of more than 1 year of duration. See image page in Commons for percentages in numbers. Reference:
  75. ↑ World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.1. ISBN   978-9283204299.
  76. ↑ Ettinger DS, Aisner J (October 2006). "Changing face of small-cell lung cancer: real and artifact". Journal of Clinical Oncology. 24 (28): 4526–4527. doi: 10.1200/jco.2006.07.3841 . PMID   17008688.
  77. ↑ Muscat JE, Wynder EL (January 1995). "Lung cancer pathology in smokers, ex-smokers and never smokers". Cancer Letters. 88 (1): 1–5. doi:10.1016/0304-3835(94)03608-l. PMID   7850764.
  78. ↑ Richards S (7 February 2019). "A new focus on small cell lung cancer". Fred Hutch.
  79. ↑ Augert A, Eastwood E, Ibrahim AH, Wu N, Grunblatt E, Basom R, et al. (February 2019). "Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition". Science Signaling. 12 (567): eaau2922. doi:10.1126/scisignal.aau2922. PMC   6530478 . PMID   30723171.
  80. ↑ "Dustin Diamond, 'Saved by the Bell' Star, Dead at 44". Entertainment Tonight. February 2021. Retrieved 2021-02-06.
  81. ↑ "Asbjørn Sennels". Ekstra Bladet[Extra Magazine] (in Danish). 9 July 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.